Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

When the FDA declared an Ozempic and Wegovy shortage, business boomed for pharmacies making cheaper, off-brand versions of ...

People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition ...